Sunesis Pharmaceuticals Reports Third Quarter 2015 Financial Results and Recent Highlights
"We continue to work diligently to complete and submit an MAA by year end for approval of vosaroxin in
Third Quarter 2015 Highlights
Received European regulatory guidance regarding potential marketing authorization application for Vosaroxin in AML and Announced Expected Submission of MAA Filing before Year End. In
July 2015, Sunesis announced that, following pre-submission advisory meetings to discuss the potential submission of a Marketing Authorization Application (MAA) for vosaroxin in Europe, the company is proceeding with an MAA filing. The MAA will focus on the indication of relapsed/refractory acute myeloid leukemia (AML) in patients age 60 years and older, a population with the greatest medical need and for whom the greatest benefit was observed in the vosaroxin/cytarabine treatment arm of VALOR, the company's pivotal Phase 3 study of vosaroxin in adult patients with relapsed or refractory AML. In October, the company confirmed that it intends to submit an MAA for vosaroxin by the end of 2015.
Announced Poster Presentation of VALOR Responder Survival Analysis at the Chemotherapy Foundation Symposium. Yesterday, Sunesis announced that results from a responder survival analysis of the VALOR trial were presented in a poster presentation at the 2015 Chemotherapy Foundation Symposium (CFS) in
New York City. The analysis examined the impact of complete remission status on overall survival. Results showed that CR status was the strongest independent predictor of overall survival in patients enrolled in the study, regardless of study arm, with median survival for patients in CR lasting more than 12 months longer than patients without a CR. Furthermore, the addition of vosaroxin to cytarabine demonstrated a two-fold increase in CR rate by day 60. The CR benefit conveyed by vosaroxin was consistently beneficial across all pre-specified subgroups, including in patients with the high unmet medical need, such as those over 60 years of age and those with refractory or relapsed disease. The poster presentation, titled "Impact of Complete Remission on Overall Survival in Patients with Refractory/Relapsed Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine: Responder Analysis for the Phase 3 VALOR Trial," will be available at www.sunesis.com following the conclusion of the symposium.
Announced Presentations at the
Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Sunesis recently announced that two poster presentations from the company's proprietary kinase inhibitor programs will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 5-9in Boston, Massachusetts. The presentations on November 8thwill include preclinical data from the company's selective PDK1 inhibitors SNS-229 and SNS-510, as well as the company's potent noncovalent second-generation BTK inhibitor, SNS-062.
Announced Oral Presentation of VALOR Analysis at the 77th Annual Meeting of the
Japanese Society of Hematology. In October, Sunesis announced that data from an analysis of the company's VALOR trial, evaluating vosaroxin in older patients with AML, were presented at the AML Clinical Trial Oral Session of the 77th Annual Meeting of the Japanese Society of Hematology(JSH) in Kanazawa, Japan. The data presented at JSH, which show a compelling survival benefit, durable responses and tolerability profile in patients age 60 years and older, were first presented at the European Hematology Association Congressin June 2015.
Announced Publication of Vosaroxin Phase 3 VALOR Trial Results in The Lancet Oncology. In August, Sunesis announced that results from the company's Phase 3 VALOR trial were published in The Lancet Oncology. The article, titled "Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study" is available online and appeared in the
September 2015print issue of The Lancet Oncology. The published results describe how although overall survival (OS) did not reach a significant difference based on the primary unstratified log-rank analysis of the endpoint, vosaroxin plus cytarabine, based on other prespecified analyses did show an overall survival benefit in relapsed/refractory AML, with the greatest benefit observed in patients older than 60 years, a population with limited treatment options.
Received feedback from
FDAregarding NDA filing for Vosaroxin in AML. In July 2015, Sunesis announced that, following a recent meeting with the U.S. Food and Drug Administration( FDA), the FDArecommended that the company provide additional clinical evidence to support a future NDA submission. The company is currently evaluating and refining its plan to gain marketing approval in the U.S. based on this feedback.
Cash, cash equivalents and marketable securities totaled
$30.5 millionas of September 30, 2015, as compared to $43.0 millionas of December 31, 2014. The decrease of $12.5 millionwas primarily due to $29.5 millionof net cash used in operating activities and $1.6 millionof principal payments against notes payable, partially offset by $18.6 millionraised from the sale of common stock through the company's at-the-market facility with Cantor Fitzgerald & Co.and from option exercises. This capital is expected to be sufficient to fund the company to the middle of 2016.
Revenue for the three and nine months ended
September 30, 2015was $0.7 millionand $2.4 millionas compared to $0.9 millionand $4.8 millionfor the same periods in 2014. Revenue in each period was primarily due to deferred revenue recognized related to the royalty agreement with Royalty Pharma.
Research and development expense was
$5.3 millionand $16.1 millionfor the three and nine months ended September 30, 2015as compared to $6.9 millionand $21.7 millionfor the same periods in 2014. The decreases between the comparable three and nine month periods were primarily due to reductions in clinical trial expenses, consulting and other outside services costs in each case.
General and administrative expense was
$4.0 millionand $14.3 millionfor the three and nine months ended September 30, 2015as compared to $7.2 millionand $17.0 millionfor the same periods in 2014. The decreases between the comparable three and nine month periods were primarily due to decreases in outside services and personnel costs.
Interest expense was
$0.2 millionand $0.7 millionfor the three and nine months ended September 30, 2015as compared to $0.4 millionand $1.4 millionfor the same periods in 2014. The decreases in the 2015 periods were due to the reduced principal balance outstanding on notes payable.
Net other income was
$1.8 millionand $3.6 millionfor the three and nine months ended September 30, 2015as compared to net other expense of $1.6 millionand $6.4 millionfor the same periods in 2014. The amounts for each period were primarily comprised of non-cash credits or charges for the revaluation of warrants issued in 2010, which expired in October 2015.
Cash used in operations was
$29.5 millionfor the nine months ended September 30, 2015as compared to $34.2 millionfor the same period in 2014. Net cash used in the 2015 period resulted primarily from the net loss of $25.1 millionand changes in operating assets and liabilities of $5.6 million, partially offset by net adjustments for non-cash items of $1.2 million.
Sunesis reported loss from operations of
$8.6 millionand $28.0 millionfor the three and nine months ended September 30, 2015as compared to $13.3 millionand $33.9 millionfor the same periods in 2014. Net loss was $7.0 millionand $25.1 millionfor the three and nine months ended September 30, 2015as compared to $15.3 millionand $41.7 millionfor the same periods in 2014.
Conference Call Information
Sunesis will host an update conference call today,
About QINPREZO™ (vosaroxin)
QINPREZO™ (vosaroxin) is an anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Preclinical data demonstrate that vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Both the U.S. Food and Drug Administration (
The trademark name QINPREZO is conditionally accepted by the FDA and the EMA as the proprietary name for the vosaroxin drug product candidate.
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking statements, including statements related to Sunesis' estimated timelines for regulatory interactions and regulatory progress, including the anticipated submission of the MAA for vosaroxin with the EMA, CTA filing for SNS-062 in
|SUNESIS PHARMACEUTICALS, INC.|
|CONSOLIDATED BALANCE SHEETS|
|September 30,||December 31,|
|Cash and cash equivalents||$ 16,801||$ 22,186|
|Prepaids and other current assets||796||1,223|
|Total current assets||31,299||44,204|
|Property and equipment, net||17||42|
|Total assets||$ 31,316||$ 44,246|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable||$ 1,790||$ 3,177|
|Accrued clinical expense||1,909||3,112|
|Other accrued liabilities||2,652||3,087|
|Current portion of deferred revenue||2,441||3,418|
|Current portion of notes payable||5,861||9,257|
|Total current liabilities||16,144||27,881|
|Non-current portion of deferred revenue||1,221||2,563|
|Non-current portion of notes payable||1,893||--|
|Additional paid-in capital||559,847||536,499|
|Accumulated other comprehensive loss||(2)||(7)|
|Total stockholders' equity||12,058||13,802|
|Total liabilities and stockholders' equity||$ 31,316||$ 44,246|
|Note 1: The consolidated balance sheet as of December 31, 2014 has been derived from the audited financial statements as of that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.|
|SUNESIS PHARMACEUTICALS, INC.|
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|AND COMPREHENSIVE LOSS|
|(In thousands, except per share amounts)|
Three months ended
Nine months ended
|License and other revenue||$ 683||$ 854||$ 2,391||$ 4,838|
|Research and development||5,259||6,939||16,073||21,697|
|General and administrative||3,994||7,226||14,280||17,030|
|Total operating expenses||9,253||14,165||30,353||38,727|
|Loss from operations||(8,570)||(13,311)||(27,962)||(33,889)|
|Other income (expense), net||1,782||(1,623)||3,569||(6,382)|
|Unrealized gain (loss) on available-for-sale securities||3||(2)||5||(6)|
|Comprehensive loss||$ (7,018)||$ (15,327)||$ (25,093)||$ (41,685)|
|Basic and diluted loss per common share:|
|Net loss||$ (7,021)||$ (15,325)||$ (25,098)||$ (41,679)|
|Shares used in computing basic and diluted loss per common share||74,776||60,549||71,670||59,052|
|Basic and diluted loss per common share||$ (0.09)||$ (0.25)||$ (0.35)||$ (0.71)|
CONTACT: Investor and Media Inquiries:
David Pitts Argot Partners212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc.650-266-3717